TruDiagnostic is a health data company and CLIA certified lab specializing in understanding and interpreting the fluid epigenome
Doctors in the U.S. can now access a novel NAD+ blood diagnostic for their patients. This is thanks to the launch of a new partnership with epigenetic laboratory TruDiagnostic and Finland-based NAD diagnostic company NADMED. NADMED’s accuracy and methodology has recently made waves in the international NAD+ diagnostic market by being the only EU approved NAD+ testing kit.
As many healthcare providers already know, NAD+/NADH is a metabolite with a significant relationship to aging and many other diseases. Abnormal levels of these metabolites have been linked to Improper Immune Function, Metabolic Disease, Dementia & Neurodegeneration, Heart Disease, and more. NAD+/NADH is essential to sustaining optimal function, and levels in your body markedly decline with age.
TruDiagnostic decided to partner with NADMED for their test accuracy and reliability. The Q-NADMED Blood Kit is CE-marked for measuring NAD+ and NADH from a small blood sample for a range of clinical purposes. The Q-NADMED Blood Kit is the only method for the NAD measurement to have received a CE-marking. This high level of reliability is consistent with the internal standard of TruDiagnostic.
“We appreciate TruDiagnostic’s agile, yet diligent approach to introducing a novel technology to their customers in the US market. We foresee a fruitful cooperation to continuously develop business and service models to meet the needs for NAD testing of the varied customer base,” says Jari Närhi, NADMED CEO and Co-Founder.
Additional competitive advantages for NADMED rest in the extraction technique, which is simple and robust, and works with blood samples; and a quick and reliable detection method. Another advantage of NADMED testing kits is that it allows accurate, quantitative detection of metabolites in a sample due to know-how regarding preparation and preservation of NAD standards used in the kit.
Source: Company Press Release